close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ionis Pharmaceuticals, Inc.

< Previous 1 2 Next >
News headline image
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis to hold first quarter 2026 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis announces changes to Board of Directors
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis updates time for fourth quarter and full year 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis to hold fourth quarter and full year 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis reports third quarter 2025 financial results and highlights progress on key programs
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis to hold third quarter 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.